James F. Howard, MD, discusses what he believes will be the next steps in treating myasthenia gravis.
James Howard, MD
Advertisement
Articles by James Howard, MD
James F. Howard, MD, discusses the significance of the FDA expanding the label for efgartigimod in patients with generalized myasthenia gravis (gMG).
A retrospective analysis of Medicare claims was used to study emergency department (ED) dispositions, specifically evaluating inpatient admissions compared with home health referrals.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Awareness Gaps Drive Narcolepsy, IH Delays: Logan Schneider, MD
2
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
3
Former USAID Health Chief Says Aid Cuts Are Costing Children's Lives
4
Povetacicept Cuts Proteinuria by 52% in IgA Nephropathy at Week 36
5